AptivusTreatment for HIV Infection
FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir
GAITHERSBURG, Md., May 19, 2005 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee recommended the approval of the investigational anti-HIV drug tipranavir (11-3). Tipranavir is a non-peptidic protease inhibitor that requires boosting with low-dose ritonavir and must be used in combination with other antiretroviral agents.
"We are pleased with the committee's recommendation and commend its thorough discussion of the tipranavir clinical data," said Burkhard Blank, M.D., Senior Vice President, Medical and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We look forward to working with the FDA on the comments raised by the Advisory Committee and on the next steps of the application review process."
The committee's positive recommendation is based on data from two large, well-controlled Phase 3 clinical trials, RESIST-1 and RESIST-2, conducted in protease inhibitor (PI)-resistant treatment-experienced patients. These patients had taken three classes of anti-HIV drugs and were failing their PI-based regimen at the time of study entry. These trials examine the treatment response of tipranavir boosted with ritonavir (TPV/r) versus a comparator group in which patients received one of several marketed ritonavir-boosted PIs. In addition, patients in both arms received an optimized background regimen of other antiretroviral drugs.
The committee's recommendations will be considered by the FDA in its review of the New Drug Application that Boehringer Ingelheim submitted for tipranavir. The FDA is not bound by the committee's recommendation, but takes its advice into consideration when reviewing investigational drugs seeking approval.
Boehringer Ingelheim will continue to provide tipranavir to eligible patients prior to its commercial availability through a Compassionate Use Program, which is being run as an Expanded Access Program in the U.S.
Tipranavir is a non-peptidic protease inhibitor currently in late Phase 3 clinical development. Boehringer Ingelheim submitted a New Drug Application for tipranavir to the U.S. Food and Drug Administration in late 2004 that was granted a priority, six-month review in February 2005.
Based on available clinical and in vitro data, tipranavir/r appears to retain activity against many strains of HIV-1 that are resistant to commercially available protease inhibitors. These findings are currently being further evaluated in ongoing studies. Tipranavir/r is also being evaluated for use in pediatric and treatment-naive patient populations in Phase 2 and 3 studies that are currently underway.
The most commonly (greater than or equal to 1%) reported adverse events in patients across all tipranavir clinical trials to date are gastrointestinal, including diarrhea, nausea and vomiting, as well as fatigue and headache. Mild rash occurred more often in women than in men. The most common (greater than or equal to 2%) grade 3/4 laboratory abnormalities in patients are elevated liver enzymes and lipids. Patients treated with tipranavir/r experienced a significantly higher rate of liver enzyme and lipid elevations; however, most laboratory abnormalities were asymptomatic and most patients were successfully treated without discontinuation.
Tipranavir co-administered with low-dose ritonavir, has been associated with reports of clinical hepatitis and hepatic decompensation, including some fatalities. These have generally occurred in patients with advanced HIV disease taking multiple concomitant medications. A causal relationship to tipranavir could not be established.
Ongoing studies will continue to evaluate the safety and efficacy of tipranavir/r.
Tipranavir does not cure HIV infection/AIDS or prevent the transmission of HIV to others. There are no study results demonstrating the effects of tipranavir on the clinical progression of HIV.
Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. Viramune (nevirapine), a product of original research done at Boehringer Ingelheim, was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs. Boehringer Ingelheim is involved in basic research and is committed to the development of tipranavir and improving HIV therapy by providing physicians and patients with innovative antiretrovirals.
For more information on Boehringer Ingelheim, please visit the Boehringer Ingelheim website.
Posted: May 2005
- New Aptivus (tipranavir) Oral Solution Approved forTreatment-Experienced Pediatric and Adolescent HIV Patients - June 24, 2008
- Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA - October 5, 2007
- FDA Approves Aptivus for HIV Infection - June 22, 2005
- Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir - October 25, 2004